Infoglim MV 2mg/500mg/0.2mg Tablet SR
Marketer
Vats Biotech Pvt Ltd
Salt Composition
Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.2mg)
Overview Infoglim MV 2mg/500mg/0.2mg Tablet SR
Diabexe Trio 2mg/500mg/0.2mg Extended-Release Tablets are classified as antidiabetic medications. This combination therapy is indicated for adult patients with type 2 diabetes mellitus to manage blood glucose levels. Diabexe Trio should be ingested with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on your glycemic response. Continued use is crucial; discontinuation without medical consultation risks elevated blood sugar, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. Remember, this medication complements a comprehensive diabetes management plan encompassing diet, exercise, and weight control as directed by your doctor. Lifestyle modifications are integral to diabetes control. Hypoglycemia (low blood sugar) is the most prevalent side effect, characterized by sweating, dizziness, headache, and tremors. Regular meals and readily available glucose sources (e.g., sugary snacks, fruit juice) are essential for prevention. Alcohol consumption should be limited due to its potential to exacerbate hypoglycemia. Additional potential side effects include altered taste, nausea, diarrhea, abdominal pain, headache, edema, blurred vision, fractures, and upper respiratory infections. Weight gain may also occur. This medication is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe renal or hepatic impairment. Prior heart conditions should be disclosed to your physician before commencing treatment. Consult your doctor before use if pregnant or breastfeeding. Regular blood glucose monitoring, along with periodic blood tests to assess blood cell counts and liver function, are recommended.
Primary Ingredients of Infoglim MV 2mg/500mg/0.2mg Tablet SR
No text provided to rephrase.
Uses of Infoglim MV 2mg/500mg/0.2mg Tablet SR
Managing type 2 diabetes
Major Benefits of Infoglim MV 2mg/500mg/0.2mg Tablet SR:
Administer this medication precisely as prescribed by your physician, adhering to both the dosage and treatment duration. The tablet should be swallowed whole; avoid chewing, crushing, or breaking it. Infoglim MV 2mg/500mg/0.2mg Extended-Release Tablet is intended for consumption on an empty stomach.
Common Side effects of Infoglim MV 2mg/500mg/0.2mg Tablet SR:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Infoglim MV 2mg/500mg/0.2mg Tablet SR:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the entire tablet without chewing, crushing, or fracturing it. Infoglim MV 2mg/500mg/0.2mg Sustained-Release Tablets should be taken on an empty stomach.
How Infoglim MV 2mg/500mg/0.2mg Tablet SR works:
Infoglim MV SR tablets (2mg/500mg/0.2mg) contain a triple-action antidiabetic formulation.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent alcohol use and Infoglim MV 2mg/500mg/0.2mg Tablet SR is inadvisable.
PregnancyCONSULT YOUR DOCTOR
The use of Infoglim MV 2mg/500mg/0.2mg SR tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The extended-release Infoglim MV 2mg/500mg/0.2mg tablet likely poses a risk during lactation. Available human data indicate potential transfer to breast milk, possibly harming the infant.
DrivingCAUTION
Driving may be impaired by excessively low or high blood glucose levels. Refrain from driving if such symptoms arise.
KidneyUNSAFE
The use of Infoglim MV 2mg/500mg/0.2mg SR tablets is likely inadvisable for individuals with kidney impairment and should be omitted. Medical advice is recommended. Furthermore, its administration is contraindicated in patients exhibiting severe renal dysfunction.
LiverCAUTION
Patients with liver impairment should use Infoglim MV 2mg/500mg/0.2mg Tablet SR cautiously, potentially requiring dosage modification. A physician's consultation is recommended. For individuals with mild to moderate liver disease, initiation with a reduced Infoglim MV 2mg/500mg/0.2mg Tablet SR dose is typical; however, its use is contraindicated in those with severe liver disease.
What if you forget to take Infoglim MV 2mg/500mg/0.2mg Tablet SR :
Should you forget a dose of Infoglim MV 2mg/500mg/0.2mg SR Tablet, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Infoglim MV 2mg/500mg/0.2mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently